Sucampo Pharmaceuticals, Inc.
SCMP
SCMP was delisted on the 12th of February, 2018.
188 hedge funds and large institutions have $645M invested in Sucampo Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 52 increasing their positions, 56 reducing their positions, and 41 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
79% more capital invested
Capital invested by funds: $360M → $645M (+$286M)
40% more call options, than puts
Call options by funds: $11.5M | Put options by funds: $8.23M
27% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 41
6% more funds holding
Funds holding: 178 → 188 (+10)
7% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 56
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Paulson & Co
New York
|
+$19.7M |
| 2 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$18.4M |
| 3 |
JP Morgan Chase
New York
|
+$12.1M |
| 4 |
PCM
Prelude Capital Management
New York
|
+$8.23M |
| 5 |
Renaissance Technologies
New York
|
+$8.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$22M |
| 2 |
KAM
Krensavage Asset Management
New York
|
-$18.8M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$14.8M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$7.2M |
| 5 |
Goldman Sachs
New York
|
-$6.07M |
SCMP Hedge Fund Activity: Q4 2017 in Review
188 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Sucampo Pharmaceuticals, Inc. (SCMP) for Q4 2017, worth a combined $645M — up 79% from $360M a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new SCMP positions and 41 closed out — a net gain of 11 holders — while 52 added to existing stakes and 56 trimmed.
The largest buyer was Paulson & Co, opening a new position worth an estimated $19.7M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $22M sold.
- 188 institutional investors held Sucampo Pharmaceuticals, Inc. (SCMP) as of Q4 2017, up from 178 in Q3 2017.
- Funds reported $645M of Sucampo Pharmaceuticals, Inc. stock for Q4 2017, up 79% quarter-over-quarter.
- 52 funds opened new Sucampo Pharmaceuticals, Inc. positions in Q4 2017 and 41 closed out, a net change of +11 holders.
- The largest Sucampo Pharmaceuticals, Inc. buyer in Q4 2017 was Paulson & Co, an estimated $19.7M added.
- The largest Sucampo Pharmaceuticals, Inc. seller in Q4 2017 was Point72 Asset Management, an estimated $22M sold.
Based on aggregated 13F filings for Q4 2017.